Search for European Projects

13 European Projects Found

Searched on 125080 European Projects

 FINISHED 
The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of intracerebrally administered CDNF protein therapy in patients with Parkinson’s disease (PD), using a neurosurgically implanted Drug Delivery System (DDS), which will also be clinically validated in the study. Thus the TreatER project has two independent goals, ei ...
Read Project

 12

 FINISHED 
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Read Project

 34

 FINISHED 
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 

Oral biopharmaceutics tools (ORBITO)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project

 28

 FINISHED 
The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 
CHEM21 is a project that will develop a broad based portfolio of sustainable technologies for green chemical intermediate manufacture aimed at the pharmaceutical industry. Initially working with the EFPIA members the collaborators of CHEM21 will analyse a number of projects that are in development to decide which the priorities are for technology development. This analysis will also be used to upd ...
Read Project

 19

 FINISHED 

European Medicines Research Training Network (EMTRAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Read Project

 32

 FINISHED 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Start date: Sep 1, 2009, End date: Jun 30, 2016,

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Read Project

 24

 FINISHED 
Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel th ...
Read Project

 23

 FINISHED 
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Read Project

 20

 FINISHED 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Start date: May 1, 2009, End date: Apr 30, 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project

 52

 FINISHED 

Prostate cancer: profiling and evaluation of ncRNA (ProspeR)

Start date: Feb 1, 2008, End date: Jul 31, 2012,

Annually, over 200 000 new prostate cancer cases are diagnosed in Europe. This number is expected to further increase due to widespread use of prostate specific antigen (PSA) tests on asymptomatic men and an aging population. This leads to high rate of over-detection, where most cases will never experience cancer symptoms during their lifetime. Hence, our current lack of means to predict prostate ...
Read Project

 8